1. |
Stealth nucleosides in the treatment of viral diseases |
|
Inpharma Weekly,
Volume &NA;,
Issue 1388,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
2. |
Contemporary approaches in treating chronic hepatitis C |
|
Inpharma Weekly,
Volume &NA;,
Issue 1388,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
3. |
A sensitive and specific diagnostic test for SARS*will be available in 6−12 months, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1388,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
4. |
Ramipril: clinical, economic advantages in diabetes, stable angina |
|
Inpharma Weekly,
Volume &NA;,
Issue 1388,
2003,
Page 5-6
&NA;,
Preview
|
|
摘要:
It is estimated that there are currently about 17.2 million individuals with diabetes mellitus in the US, of which type 2 diabetes accounts for 90−95% of cases. Individuals with diabetes are at high risk of developing hypertension, heart disease, stroke, myocardial infarction (MI) and other complications. Furthermore, the risk of cardiovascular death is two- to three-fold higher among women with diabetes versus those without diabetes, and three- to four-fold higher among men with versus without diabetes. Consequently, reducing the risk of such events, and the related costs, among individuals with diabetes is a pertinent issue for healthcare payers in the US. Ramipril is one of the most potent long-acting ACE-inhibitors available, and has been shown to be effective for treating all grades of hypertension and heart failure. The cost effectiveness of ramipril treatment among patients with diabetes is therefore of great interest to healthcare professionals in the US. Similarly, the risk of cardiovascular (CV) events and death is high among patients who undergo percutaneous coronary intervention (PCI) for stable angina pectoris. The benefits of ramipril therapy among these patients have been shown in large clinical trials, and the favourable cost effectiveness of such therapy will enhance its worth among certain patient populations. These issues were examined in two studies presented at the 52nd Annual Scientific Session of the American College of Cardiology [Chicago, US; March/April 2003]
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
5. |
Enoxaparin cost effective thromboprophylaxis in Spain |
|
Inpharma Weekly,
Volume &NA;,
Issue 1388,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
6. |
Some women with a first diagnosis of epithelial ovarian cancer do not receive optimal treatment"despite scientific evidence and published guidelines that advocate chemotherapy"in this patient population, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1388,
2003,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
7. |
Decitabine plus busulfan and cyclophosphamide may be an effective preparative regimen before stem cell transplantation in patients with leukaemia, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1388,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
8. |
Solifenacin succinate promising in overactive bladder |
|
Inpharma Weekly,
Volume &NA;,
Issue 1388,
2003,
Page 9-10
Poole Raewyn,
Preview
|
|
摘要:
Solifenacin succinate [YM 905], an investigational long-acting antimuscarinic agent, is effective and well tolerated in patients with overactive bladder, according to results from three phase III studies presented at the Annual Meeting of the American Urological Association [Chicago, US; April−May 2003]. These studies, involving more than 2000 patients, showed that solifenacin succinate significantly reduced urinary urgency, incontinence and frequency, compared with placebo. More than half of the patients treated with solifenacin succinate became continent by the end of the study. Another important finding was that the increase in the volume of each micturition among patients treated with solifenacin succinate was 3−6 times that observed in placebo recipients."Solifenacin succinate may give physicians another option to help... patients cope with the embarrassing and bothersome symptoms of incontinence that severely impact on quality of life",said Dr Joel Kaufman from Urology Research Options in Aurora, US.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
9. |
Long-term results of ADA gene therapy |
|
Inpharma Weekly,
Volume &NA;,
Issue 1388,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
10. |
Heparin-coated stents: superior angiographic results |
|
Inpharma Weekly,
Volume &NA;,
Issue 1388,
2003,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|